Scholarlink

Background <p>Despite the well-established efficacy of injectable insulin in achieving and maintaining optimal glycaemic control, its acceptance among people living with diabetes (PWD) in India remains disproportionately low. Delayed or inadequate insulin therapy often results in prolonged poor glycaemic control, increasing the risk of diabetes-related complications and contributing to a higher healthcare burden.</p> Objective <p>This review aims to examine key barriers to the initiation and intensification of injectable insulin therapy in India and to explore strategies to address these challenges.</p> Methods <p>A narrative review of the existing literature was conducted to identify barriers influencing the use of injectable insulin. Barriers were categorized into patient-related, healthcare provider (HCP)-related, and healthcare system–related factors.</p> Results <p>Multiple interrelated barriers were identified. Patient-related barriers include fear of injections, social stigma, and misconceptions regarding insulin therapy. HCP-related barriers involve clinical inertia and limited time for patient education, which delay insulin initiation and intensification. System-level barriers include challenges related to access, affordability, and resource constraints within the healthcare infrastructure. Emerging strategies to overcome these obstacles include structured patient education, focused HCP training, healthcare policy interventions, and innovations such as non-invasive insulin delivery systems.</p> Conclusion <p>Overcoming barriers to injectable insulin therapy requires a comprehensive, multi-stakeholder approach. Integration of educational, clinical, policy, and technological strategies may improve insulin acceptance and optimize diabetes management outcomes in India.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bridging the gap: understanding barriers to injectable insulin in India

  • 期刊论文

  • 发表日期：

    2026年5月18日

查看全文
  • Banshi Saboo,
  • Anuj Maheshwari,
  • Jothydev Kesavadev,
  • Aravinda Jagadeesha,
  • Mathew John,
  • Om Lakhani,
  • Surendra K. Sharma,
  • Girish Parmar,
  • Tejal Lathia,
  • Aneesh Ghosh,
  • Nilakshi Deka,
  • Anita Nambiar,
  • A Shanmugam,
  • Lakshmi Nagendra,
  • Nanditha Arun,
  • Rahul Iyer,
  • Amarnath Sugumaran,
  • Senthilnathan Mohanasundaram

摘要

Background

Despite the well-established efficacy of injectable insulin in achieving and maintaining optimal glycaemic control, its acceptance among people living with diabetes (PWD) in India remains disproportionately low. Delayed or inadequate insulin therapy often results in prolonged poor glycaemic control, increasing the risk of diabetes-related complications and contributing to a higher healthcare burden.

Objective

This review aims to examine key barriers to the initiation and intensification of injectable insulin therapy in India and to explore strategies to address these challenges.

Methods

A narrative review of the existing literature was conducted to identify barriers influencing the use of injectable insulin. Barriers were categorized into patient-related, healthcare provider (HCP)-related, and healthcare system–related factors.

Results

Multiple interrelated barriers were identified. Patient-related barriers include fear of injections, social stigma, and misconceptions regarding insulin therapy. HCP-related barriers involve clinical inertia and limited time for patient education, which delay insulin initiation and intensification. System-level barriers include challenges related to access, affordability, and resource constraints within the healthcare infrastructure. Emerging strategies to overcome these obstacles include structured patient education, focused HCP training, healthcare policy interventions, and innovations such as non-invasive insulin delivery systems.

Conclusion

Overcoming barriers to injectable insulin therapy requires a comprehensive, multi-stakeholder approach. Integration of educational, clinical, policy, and technological strategies may improve insulin acceptance and optimize diabetes management outcomes in India.